Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5699335 | Clinical Oncology | 2010 | 11 Pages |
Abstract
Ongoing management recommendations must be tailored to realistic, evolving risk estimates that are actively updated during follow-up. By individualizing therapy on the basis of initial and ongoing risk assessments, we can maximize the beneficial effects of aggressive therapy in patients with thyroid cancer who are likely to benefit from it, while minimizing potential complications and side effects in low-risk patients destined to have a full healthy and productive life after minimal therapeutic intervention.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
H. Tala, R.M. Tuttle,